A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 Years in Korea

Name: A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 Years in Korea
Creator: Vivli
Published: 2025-03-04 16:14:10
License: 暂无描述

DataCite Commons2025-03-04 更新2026-05-07 收录

下载链接：

https://search.vivli.org/doiLanding/studies/PR00010353/isLanding

下载链接

链接失效反馈

官方服务：

资源简介：

The purpose of the study was to assess the immunogenicity and safety of two doses of Novartis Meningococcal B Recombinant (rMenB+OMV NZ) vaccine administered one month apart (0, 1 month schedule) in Korean adolescents aged between 11 to 17 years.

提供机构：

Vivli

创建时间：

2024-07-24